Standard Oxytocin Versus High Dose Oxytocin to Control Postpartum Hemorrhage in High Risk Pregnancy During Elective Cesarean Section
NCT ID: NCT06560099
Last Updated: 2024-08-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
39 participants
INTERVENTIONAL
2024-08-25
2025-04-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Oxytocin to Decrease Blood Loss During Cesarean Section
NCT00891150
Does the Rapid Intravenous Administration of Oxytocin After Delivery of the Baby Decrease the Bleeding During Cesarean Section in Women at Risk of Bleeding During Cesarean Section?
NCT00257803
Uterotonics Using to Reduce Bleeding at Cesarean Section
NCT02562300
Oxytocin Administration During Cesarean Section
NCT03344302
Oxytocin i.m./i.v. Versus Carbetocin i.v. in Elective Cesarean Sections
NCT03651882
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A (standard oxytocin dose)
Oxytocin
will receive 10 IU oxytocin intravenous bolus over one min and infusion of 10 IU oxytocin in 500 ml of 0.9 saline over four hours.
Group B (high dose oxytocin)
Oxytocin
will receive 10 IU oxytocin intravenous bolus over one min and infusion of 10 IU oxytocin in 500 ml of 0.9 saline over four hours.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oxytocin
will receive 10 IU oxytocin intravenous bolus over one min and infusion of 10 IU oxytocin in 500 ml of 0.9 saline over four hours.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* History of postpartum hemorrhage
* Placental disorders ie: placenta previa
* Infertility and ICSI
* High Parity
* History of Endometriosis
* Fetal disorders (IUGR, IUFD, Preterm, Congenital anomalies, oligohydramnios or polyhydramnios, macrosomia)
* Preterm labor on uterine relaxants
* Twins pregnancy
* Patients on antiplatelets and anticoagulants
* Uneventful antenatal care
Exclusion Criteria
* Normal uncomplicated pregnancy
* Emergency cesarean section
* Exhausted uterus due to trial of normal labor
* Couvelaire uterus
20 Years
45 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
RAMY AHMED
Assistant Professor of Anesthesia
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Laura 1 protocol
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.